Clinical Trial Coordinator Memory

clinical-trial-coordinator-memory · 30 facts · by uniqent · 0 installs

30 GCP-verified facts covering FDA SAE reporting timelines, ICH E6(R3) requirements, EDC/CTMS platforms, IRB compliance, eTMF management, and enrollment KPIs for Phase I-III clinical trials.

clinical-trials

pharma

life-sciences

regulatory

compliance

Memory brain

Drag to pan · scroll to zoom · drag a node · hover to highlight · click to focus.

fact

ICH E6(R3) was finalized in January 2025, replacing E6(R2); its Annex 2 on novel trial designs is expected in 2026 and adds guidance on decentralized-clinical-trials and adaptive-designs

fact

FDA requires fatal or life-threatening unexpected SUSAR reports to be submitted within 7 calendar days of sponsor awareness under 21 CFR 312.32

fact

Non-fatal unexpected SAEs related to an IND must be reported to FDA within 15 calendar days of sponsor determination per 21 CFR 312.32(c)(2)

fact

IRB continuing review must be completed at least annually for most studies; OHRP guidance allows waiver of annual continuing review for minimal-risk studies

fact

Medidata Rave is the most widely deployed EDC platform in Phase II–III oncology trials globally; query resolution SLA is typically 48–72 hours per sponsor SOPs

fact

Veeva Vault eTMF holds the Trial Master File in regulated digital format; each document must be classified against DIA TMF Reference Model 3.0 before upload

fact

Site screen failure rates above 40% in oncology typically trigger a site coaching visit and amendment review; average industry screen failure rate is 20–35% depending on indication

fact

A typical Phase III multi-site EDC setup requires 8–16 weeks of build time and UAT before first patient first visit

fact

Protocol deviations must be categorized as major or minor; major deviations affecting subject safety or data integrity are reportable to the IRB and typically to the sponsor within 5–10 business days

fact

GCP training under ICH E6(R3) must be documented per investigator and coordinator; missing training records are a Tier 1 inspection finding

fact

eConsent platforms (e.g., Veeva Vault, Medidata Patient Cloud) are accepted by FDA as long as the process meets 21 CFR Part 11 electronic signature requirements

fact

CTMS platforms like Veeva CTMS and Medidata CTMS track site activation status, enrollment targets, monitoring visits, and milestone payments in one dashboard

fact

The FDAAA 801 registration requirement mandates that most Phase II–IV trials be registered on ClinicalTrials.gov within 21 days of first patient enrollment

fact

Results posting on ClinicalTrials.gov is required within 12 months of primary completion date under FDAAA 801; failure can trigger FDA action letters and NIH funding holds

fact

Source Document Verification (SDV) by monitors should cover 100% of safety and primary endpoint data points; risk-based monitoring (RBM) may reduce SDV to 10–20% for secondary endpoints

fact

Risk-Based Monitoring under ICH E6(R3) and FDA 2023 RBM guidance recommends a centralized statistical review layer alongside on-site SDV to detect systemic data issues

fact

DEA Schedule II investigational drugs require a separate drug accountability log and biennial DEA registration renewal at each investigational site

fact

Serious Adverse Event (SAE) definition per ICH E2A: death, life-threatening event, hospitalization, disability, congenital anomaly, or medically important event

fact

DSMB (Data Safety Monitoring Board) reviews unblinded interim safety data for Phase III trials; the CTC must provide clean data snapshots to the DSMB coordinator per the charter schedule

fact

Informed Consent Form must be re-obtained when a protocol amendment materially changes risk or procedures; IRB approval is required before the revised ICF is used

fact

Oracle Clinical One and REDCap are common EDC platforms for academic and smaller investigator-initiated trials where cost per site is a constraint

fact

Site activation timelines from CTA execution to first patient screened average 3–6 months in the US, 6–9 months in EU due to regulatory authority review layers

fact

21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated trials; systems must maintain audit trails, access controls, and record integrity

fact

Enrollment velocity is measured as patients screened per site per month; top-quartile sites in oncology trials enroll 2–4x more than median sites

fact

eTMF inspection readiness requires documents classified, QC'd, and filed within 5 business days of receipt; late filing is a common Form 483 observation at FDA inspections

fact

SUSAR distribution to investigators must occur within 15 days of sponsor awareness for non-fatal events; expedited distribution within 7 days for fatal/life-threatening

fact

COVID-19 pandemic normalized decentralized clinical trials (DCT) with remote consent, home nursing visits, and direct-to-patient drug shipment; FDA DCT guidance (May 2023) codified these practices

fact

Adaptive trial designs under FDA Adaptive Designs guidance (2019) allow pre-specified sample size re-estimation and seamless Phase II/III designs; the CTC must track adaptation trigger data separately

fact

CRO oversight responsibilities under ICH E6(R3) remain with the sponsor even when fully delegated; the sponsor must maintain a quality oversight plan and audit schedule

fact

The average cost of a Phase III trial is $41–$50 million; site initiation costs per site average $200,000–$400,000 including staff training, equipment, and startup visits

memory entity tag

Add to a brain

In Uniqent Studio: Memory → Browse memory hub → add this pack's facts to your brain.

GET https://uniqent.ai/api/v1/memory/clinical-trial-coordinator-memory